DHS 115.03(4)(4) “Medical consultant” means a physician licensed to practice medicine or osteopathy under ch. 448, Stats., who has expertise in treatment of one or more of the conditions listed under s. DHS 115.04. DHS 115.03(5)(5) “Metabolic disorder” means a disorder of the chemical processes that take place in the body. DHS 115.03(6)(6) “Screening” means checking each member of a population to identify presumptive medical conditions that indicate that diagnostic testing for congenital or metabolic disorders is needed. DHS 115.03 HistoryHistory: Cr. Register, May, 1993, No. 449, eff. 6-1-93; correction in (2) made under s. 13.92 (4) (b) 6., Stats., Register January 2009 No. 637; CR 14-074: am. (3) Register July 2015 No. 715, eff. 10-1-15. DHS 115.04DHS 115.04 Congenital disorders. Pursuant to s. 253.13 (1), Stats., blood samples taken from each newborn shall be tested for all of the following conditions: DHS 115.04(4)(4) Hemoglobinopathies, including all of the following: DHS 115.04(6)(6) Congenital adrenal hyperplasia, ICD-10-CM-E25.0. DHS 115.04(8)(8) Fatty acid oxidation disorders, including all of the following: DHS 115.04(8)(a)(a) Medium-chain acyl-CoA dehydrogenase deficiency, ICD-10-CM-E71.311. DHS 115.04(8)(b)(b) Long-chain L-3-Hydroxy acyl-CoA dehydrogenase deficiency, ICD-10-CM-E71.318. DHS 115.04(8)(c)(c) Very long-chain acyl-CoA dehydrogenase deficiency, ICD-10-CM-E71.310. DHS 115.04(8)(cm)(cm) Carnitine palmitoyltransferase IA deficiency, ICD-10-CM-E71.318. DHS 115.04(8)(d)(d) Carnitine palmitoyltransferase II deficiency, ICD-10-CM-E71.318. DHS 115.04(8)(e)(e) Carnitine-acylcarnitine translocase deficiency, ICD-10-CM-E71.318. DHS 115.04(8)(i)(i) Medium/short-chain hydroxy CoA dehydrogenase deficiency, ICD-10-CM-E71.318. DHS 115.04(8)(j)(j) Medium-chain ketoacyl-CoA thiolase deficiency, ICD-10-CM-E71.318. DHS 115.04(11)(11) Tyrosinemia types I, II, and III, ICD-10-CM-E70.21. DHS 115.04(14)(14) Severe Combined Immunodeficiency and related conditions of immunodeficiency, ICD-10-CM-D81.9. DHS 115.04(15)(c)(c) Methylmalonic acidemia (CBL A, B, C, D; MUT), ICD-10-CM-E71.120. DHS 115.04(16)(16) Critical congenital heart disease, including all of the following: DHS 115.04(16)(g)(g) Single ventricle heart disease variants other than HLHS, including all of the following: DHS 115.04(16)(g)3.3. Congenital malformations of the tricuspid valve unspecified, ICD-10-CM-Q22.9. DHS 115.04 HistoryHistory: Cr. Register, May, 1993, No. 449, eff. 6-1-93; emerg. am. (5) and (6), cr. (7), eff. 1-31-95; correction in (intro.) made under s. 13.93 (2m) (b) 7., Stats., Register, July, 1995, No. 475; am. (5) and (6), cr. (7), Register, July, 1995, No. 475, eff. 8-1-95; am. (intro.) and (1) to (6), cr. (8), Register, December, 1999, No. 528, eff. 1-1-00; emerg. cr. (9) to (13), eff. 10-12-02; CR 02-136: cr. (9) to (13) Register March 2003 No. 567, eff. 4-1-03; emerg. cr. (14), eff. 1-1-08; CR 08-005: cr. (14) Register June 2008 No. 630, eff. 7-1-08; CR 14-074: am. (intro.), cr. (15), (16) Register July 2015 No. 715, eff. 8-1-15, and renum. (1) to (1) (a) and am., cr. (1) (b), am. (2), (3), r. and recr. (4), am. (5) to (7), r. and recr. (8), am. (9) to (14), r. and recr. (15), am. (16) Register July 2015 No. 715, eff. 10-1-15; correction in (15) (g) made under s. 35.17, Stats., Register September 2015 No. 717; EmR1920: emerg. am. (title), (intro.), cr. (8) (cm), (15m), eff. 10-15-19; CR 19-064: am. (title), (intro.), cr. (8) (cm), (15m) Register December 2019 No. 768, eff. 1-1-20; EmR2131: emerg. cr. (17), eff. 1-10-22; CR 21-051: cr. (17) Register May 2022 No. 797, eff. 6-1-22. DHS 115.05(1)(1) Procedures. The state laboratory shall establish procedures, with the approval of the department, for obtaining blood specimens for the testing required under s. 253.13 (1), Stats., and this chapter, performing tests and reporting results of tests performed to the infant’s physician and the department as required under s. 253.13 (4), Stats. DHS 115.05(2)(2) Additional tests for research and evaluation purposes. The department may direct the state laboratory to perform other tests on specimens for research and evaluation purposes related to congenital and metabolic disorders or laboratory procedures. In directing that additional testing be performed, the department shall ensure that all applicable laws relating to protection of human subjects of research are observed. DHS 115.05 HistoryHistory: Cr. Register, May, 1993, No. 449, eff. 6-1-93; corrections in (1) made under s. 13.93 (2m) (b) 7., Stats., Register, July, 1995, No. 475; CR 12-025: cr. (3) Register May 2013 No. 689, eff. 6-1-13; CR 14-074: (3) renum. to 115.055 and am. Register July 2015 No. 715, eff. 8-1-15. DHS 115.055DHS 115.055 Fees. The newborn screening sample collection card fee for testing a newborn under s. 253.13 (1), Stats., and this chapter shall be $109 to cover the costs of testing and to fund follow-up services and other activities under s. 253.13 (2), Stats.
/exec_review/admin_code/dhs/110/115
true
administrativecode
/exec_review/admin_code/dhs/110/115/04/8/i
Department of Health Services (DHS)
Chs. DHS 110-199; Health
administrativecode/DHS 115.04(8)(i)
administrativecode/DHS 115.04(8)(i)
section
true